European Commission approves Mounjaroan adjunct to diet and exercise for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Eli Lilly and Company announced that the European Commission has granted marketing authorisation for the use of Mounjaro (tirzepatide), a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, as an adjunct to diet and exercise for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
The decision follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use’s (CHMP) positive opinion issued in July 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins